Coherent Market Insights has announced new analysis on Cell Therapy Manufacturing Market Status 2021-2027 which has been prepared based on an in-depth market analysis with inputs from industry experts and top vendors in the business. The report covers the market landscape and its development prospects over the coming years. The report also contains a discussion of the key vendors operating in this market.

Request Here For PDF Brochure

Cell therapy is a very effective medicinal procedure, where human cells are injected for restoration of damaged tissue. Cell theory repairs the damaged tissues of an organ rather than producing new organ. With the use new technologies and innovation, cell therapies have gained significant traction and are recognised for potentially treating the wide range of diseases such as immune deficiency, tissue degradation and metabolic disorders. The therapy is classified into two different types. The first one is allogeneic that is cells from third party donor and the second one autologous that is cells from ones own body. The main objective of cell therapy implication is to restore the damaged cells of an organ and allow the similar functioning of damaged tissues as earlier.

Some of the clinical trials of cell therapies were established and permitted. For instance, in 2013, a stage 2 clinical trial for bone marrow transplantation was performed by rheumatoid arthritis deriving stem cells in affected knee. This technique was grown due to collaboration of the government agencies. According to the U.K. 2014 report, government funded US$15.3 million in cell therapy manufacturing market.

Market Drivers:-

The increase in number of chronic diseases would lead to growth of the cell therapy manufacturing market as many such diseases are getting treated by cell therapy. New medications are implanted and regenerative medicine is also highly adopted leading to market growth. Stem cells transplantation is one of the effective medical therapy that treats certain advance stage diseases like diabetes, cancer, arthritis, blindness, cerebral palsy, Alzheimers, autism, etc. For instance, in 2015, World Health Organization (WHO) reported the annual worldwide stem cell transplants reach up to more than 50,000 transplants in various surgeries. The new medical therapy is demanded due to increasing number of trauma and accidents leading to increasing number of surgical procedures across the world. Some of the major biopharmaceutical companies are invested in research for cell therapy. For instance, in 2018, a biopharmaceutical company named as Longeveron LL, received a grant of US$ 750,000 for stem cell therapy research from the Maryland Technology Development Corporation (TEDCO). These government funding and collaborations among companies boosts the cell therapy manufacturing market growth.

Market Opportunities:-

The adoption of cell therapy is increasing in the developing countries. As cell therapy is one of the effective methods to treat certain chronic diseases even at the advanced stage, various developing regions are adopting the method of cell therapy. This gives various opportunities for players in the cell therapy manufacturing market.

Market Restraints:-

The key factor that is declining growth of the cell therapy manufacturing market is high manufacturing cost of cell therapy. As it is not cost effective, patients tends to move towards another option restraining market growth. Moreover, the strict guidelines and regulations, as well as diverse health safety concerns over cell therapy treatment are declining the cell therapy manufacturing market growth.

Regional Analysis:-

The global cell therapy manufacturing market is segmented into North America, Latin America, Asia Pacific, Europe, Africa and Middle East. Among everyone, North America owes largest number of performed surgeries and holds the dominant position in the global cell therapy manufacturing market. North America is also developed in technologically advanced products for therapy. The Centres for Disease Control & Prevention (CDC) provided the National Health Statistics Report that states, US performed around 201,748.3 million non-surgical and surgical procedures in 2011.

Moreover, Asia Pacific is also expected to have a significant growth in the global cell therapy manufacturing market in the near future. Local players in the market would grab marginal market share due to growing patients of various chronic and infectious diseases such as cancer, HIV, hepatitis etc. and less stringent regulatory requirements. Therefore, cell therapy could be at the marginal low cost that would provide better solutions to the patients.

Key Players:-

The key players operating the global cell therapy manufacturing market are Gene Therapy Catapult EUFETS, Pharmicell, CELLforCURE Merck Group, MaSTherCell, Thermo Fisher, Dickinson and Company, Miltenyi Biotec GmBH, MEDIPOST, Cognate BioServices, PharmaCell, Lonza Group, STEMCELL Technologies, Holostem Terapie Avanazate, Bio-Rad Laboratories, Inc., Takara Bio Group, Pluristem Therapeutics, Cellular Dynamics International, Anterogen, Becton, Brammer Bio, Osiris Therapeutics, and WuXi AppTec.

Some of the key players are adopting growth strategies such as introduction of new technologies and devices to keep up the top position in the market. For instance, for treating type 1 diabetes ViaCyte, Inc. successfully implanted VC-01 an embryonic stem cell derived islet in 2014.

Buy instant copy of this research report with Flat US $ 2000 Off@ https://www.coherentmarketinsights.com/promo/buynow/1728

Main points in Cell Therapy Manufacturing Market Report Table of Content

Chapter 1 Industry Overview1.1 Definition1.2 Assumptions1.3 Research Scope1.4 Market Analysis by Regions1.5 Cell Therapy Manufacturing Market Size Analysis from 2021 to 202711.6 COVID-19 Outbreak: Cell Therapy Manufacturing Industry Impact

Chapter 2 Global Cell Therapy Manufacturing Competition by Types, Applications, and Top Regions and Countries2.1 Global Cell Therapy Manufacturing (Volume and Value) by Type2.3 Global Cell Therapy Manufacturing (Volume and Value) by Regions

Chapter 3 Production Market Analysis3.1 Global Production Market Analysis3.2 Regional Production Market Analysis

Chapter 4 Global Cell Therapy Manufacturing Sales, Consumption, Export, Import by Regions (2016-2021)Chapter 5 North America Cell Therapy Manufacturing Market AnalysisChapter 6 East Asia Cell Therapy Manufacturing Market AnalysisChapter 7 Europe Cell Therapy Manufacturing Market AnalysisChapter 8 South Asia Cell Therapy Manufacturing Market AnalysisChapter 9 Southeast Asia Cell Therapy Manufacturing Market AnalysisChapter 10 Middle East Cell Therapy Manufacturing Market AnalysisChapter 11 Africa Cell Therapy Manufacturing Market AnalysisChapter 12 Oceania Cell Therapy Manufacturing Market AnalysisChapter 13 South America Cell Therapy Manufacturing Market AnalysisChapter 14 Company Profiles and Key Figures in Cell Therapy Manufacturing BusinessChapter 15 Global Cell Therapy Manufacturing Market Forecast (2021-2027)Chapter 16 ConclusionsResearch Methodology

Request for a Sample Report

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

View original post here:

Cell Therapy Manufacturing Market | Exclusive Report on the Latest Market Trends and Development - PharmiWeb.com

CaspaCIDe safety switchcontains a CID-binding domain which is connected to the signaling domain of caspase-9. With an infusion of rimiducid, the caspase-9 domain is activated, causing selective apoptosis of the CaspaCIDe-containing cells. The purpose of this technology to help with the common adverse events (AEs) observed with the use of cellular therapies in patients with cancer, such as cytokine release syndrome (CRS) and neurotoxicity. The technology can also be administered long after the initiation of a cellular therapy.

The unique inducible caspase-9 technology covered by this agreement has the potential to reduce the risk of serious adverse events associated with cellular therapies and to improve patient outcomes, saidKaty Rezvani, MD, PhD, professor ofStem Cell Transplantation and Cellular TherapyatMD Anderson, in a press release. We have successfully applied the technology to existing cell therapies, and we look forward to the potential future applications made possible by this agreement.

Research shows that adoptive cell therapies (ACTs) lead to AEs that are more prevalent than AEs associated with radiation and chemotherapy, and the AEs from cellular therapies can last for several years. CRS, the most common toxicity, is observed with all ACTs and typically manifests as fever and chills to start. Immunosuppressive agents like glucocorticoids and anti-IL-6/IL-6 receptor antibodies are used to treat CRS, however experts still consider this AE to be a challenge in patients with cancer.2

The use of chimeric antigen receptor (CAR) T-cell therapies, T-cell receptor engineering therapies (TCR-T) and tumor-infiltrating lymphocyte (TIL) therapy can cause neurotoxicity, which has clinical characteristics like confusion, delirium, expressive aphasia, obtundation, myoclonus, and seizure. This toxicity can be concurrent with CRS, making for a bigger treatment challenge. Other AEs related to the use of cellular therapies include off-target associated with both CAR T-cell therapy, and high dose IL-2related toxicity associated with TILs.

In studies, the CaspaCIDe safety switchhas demonstrated improvement of symptoms within rimiducid 24 hours. There are 45 clinical trials ongoing at MD Anderson that may be impacted by this license agreement. Currently, MD Anderson is the site for 12 clinical trials of chimeric antigen receptor T-cell therapies, 5 trials of T-cell receptor engineering therapies, 5 studies of tumor-infiltrating lymphocytes, and 23 trial of natural killer cell therapies.1

We are excited to expand our CaspaCIDe agreement with MD Anderson to include a broader set of programs to benefit cancer patients, said Rick Fair, president and CEO of Bellicum Pharmaceuticals, in the press release. We believe that our switch technology may enhance the benefit/risk profile of cell therapies. We intend to continue to pursue opportunities to expand its use via external collaborations with other leaders in the field.

Reference:

1. MD Anderson and Bellicum announce additional license agreement for use of CaspaCIDe safety switch. News release. MD Anderson Cancer Center. September 1, 2021. Accessed September 3, 2021. https://bit.ly/38AgSHs

2. Jin Y, Dong Y, Zhang J, et al. The toxicity of cell therapy: Mechanism, manifestations, and challenges. J Appl Toxicol.2021;41(5):659-667. doi: 10.1002/jat.4100

Here is the original post:

MD Anderson Now to Offer Solution for Cellular Therapy Toxicities - Targeted Oncology

Frits van Rhee, MD, PhD, discusses future research directions with CAR T-cell therapy for the treatment of patients with multiple myeloma.

Frits van Rhee, MD, PhD, professor and director of the myeloma center at the University of Arkansas for Medical Sciences, and Charles and Clydene Scharlau Chair for Hematological Malignancies, discusses future research directions with CAR T-cell therapy for the treatment of patients with multiple myeloma.

A significant question that remains with CAR T-cell therapy in for patients with multiple myeloma is where it fits into the treatment algorithm, according to van Rhee. It is feasible that this therapy could be given early in the course of treatment, such as for patients who experience early relapse, those who are diagnosed with aggressive disease, or as a replacement for stem cell transplantation, van Rhee says.

Another future opportunity with this modality is to improve upon existing CAR T-cell therapies, van Rhee adds. Thus far, CAR T-cell therapy has been exciting due to the results obtained with only first-generation products, van Rhee notes. To build on this, it is important to examine how to make these treatments persist, and last longer in patients, as well as understand how the bone marrow microenvironment affects the efficacy of these treatments, van Rhee concludes.

Read more here:

Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma - OncLive

Patent Issued Grants Protection for Deriving Brown Adipocytes from Brown Adipose (Fat)-Derived Stem Cells

MELVILLE, N.Y., Aug. 31, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company) ( BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Japanese Patent Office has issued the Company a patent related to its metabolic ThermoStem Program.

Claims granted under the new patent cover methodologies related to brown adipocytes from human brown adipose (fat)-derived stem cells. Brown adipocytes are a type of fat tissue found in humans that regulate metabolic activity. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

We are pleased to see that we have been granted a significant patent by the Japanese Patent Office for our ThermoStem Program, said Lance Alstodt, the Companys CEO. The value of our intellectual property assets under our ThermoStem Program continues to grow as we are gaining additional international protection.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

Metabolic Program (ThermoStem): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email: [emailprotected]

See more here:

BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem Program - GuruFocus.com

The National Comprehensive Cancer Network (NCCN) has announced a significant update to the guidelines for COVID-19 vaccine administration, including a third dose, in patients with cancer, according to a press release issued by the organization.1

The recommendation indicated that several groups of individuals should be eligible for a third dose of the COVID-19 vaccine, including those with new or recurring solid tumors within 1 year of their initial vaccine dose regardless of therapy, as well as those with active hematologic malignancies. Patients who have received a stem cell transplant (SCT) or engineered cellular therapy such as CAR T-cell therapy within the past 2 years should also eligible, as well as those who are recipients of SCT on immunosuppressive therapy or with a history of graft-versus-host disease regardless of when the transplant took place.

COVID-19 can be very dangerous, especially for people living with cancer, which is why were so grateful for safe and effective vaccines that are saving lives, Robert W. Carlson, MD, chief executive officer of the NCCN, said in a press release. Our organization exists to improve the lives of people with cancer; we have a long track record for making recommendations that improve quality and length of life. We want our patients to live the longest and best lives possible, which means following the science on vaccination and mask-wearing.

The NCCN COVID-19 Vaccine Advisory Committee consists of multidisciplinary physicians across the NCCNs Member Institutions. In particular, the committee includes experts in infectious diseases, vaccine development and delivery, cancer management, and medical ethics. The recommendations, which are based on available evidence and expert consensus, have been utilized globally to aid in making management decisions over the course of the COVID-19 pandemic.

When it comes to peoples safety, we have to take every precaution, Steve Pergam, MD,

MPH, associate professor of the Vaccine and Infectious Disease Division at Fred Hutchinson

Cancer Research Center and infection prevention director at Seattle Cancer Care Alliance, as well as the co-leader of the NCCN COVID-19 Vaccination Advisory Committee, said in a press release. That means even after a third dose of vaccine, we still recommend immunocompromised peoplesuch as those undergoing cancer treatmentcontinue to be cautious, wear masks, and avoid large group gatherings, particularly around those who are unvaccinated. All of us should do our part to reduce the spread of COVID-19 and get vaccinated to protect those around us from preventable suffering.

Additional recommendations from the updated guidelines suggest that all eligible caregivers and close contacts of those with cancer should be immunized whenever possible.2 The use of all vaccines with FDA approval or emergency use authorizationincluding the Pfizer/BioNTech BNT162b2 mRNA vaccine (Comirnaty), the Moderna mRNA-1273 SARS-CoV-2 vaccine, and the Janssen Ad26.COV2.S Adenovirus vector vaccineis recommended in eligible patients by the committee.

Those who are receiving allogeneic or autologous SCT or CAR T-cell therapy will need to wait at least 3 months post-therapy before receiving the vaccine. Patients with hematologic malignancies, including those receiving cytotoxic chemotherapy such as cytarabine and anthracycline-based induction regimens for acute myeloid leukemia, need to delay inoculation until absolute neutrophil count recovery. Those who are experiencing marrow failure from their disease and/or are expected to have limited or no recovery from their therapy as well as those who are receiving long-term maintenance are able to receive the vaccine once it is available.

In solid tumors, the vaccine may be received once available for those who are undergoing treatment with cytotoxic chemotherapy, targeted therapy, checkpoint inhibitors, and other immunotherapy or radiation therapy. Those who are undergoing major surgery need to wait a few days following their surgical procedure before getting the vaccines.

The Center for Disease Control (CDC) currently recommends a third dose of the mRNA COVID-19 vaccines for individuals who are moderately to severely immunocompromised. This includes:

The CDC recommends that a third dose of the mRNA COVID-19 vaccine should be given at a minimum of 4 weeks following the second dose of either the Moderna or Pfizer vaccines. Notably, although preliminary data indicate that a third dose could augment antibody titers in an immunocompromised population of patients, those who have been diagnosed with cancer continue to be at a higher risk for infection with COVID-19 and COVID-19related complications. Even with the additional dose, infection is still possible meaning that precautions such as avoiding crowds and wearing a mask are recommended.

Read the original here:

NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network

A jury awarded a North Texas physician $7.8 million after finding his business partner locked him out of their jointly owned stem cell therapy clinic in 2018.

Wade McKenna, an orthopedic surgeon and CEO of McKenna Orthopedics and Biologics, sued his former partner Neil Riordan for conspiring to ax him from his ownership stake in the Southlake-based Riordan-McKenna Institute and transfer the companys assets to another clinic Riordan owned.

Riordan, a scientist specializing in stem-cell research, ran the Riordan Medical Institute at the same location as the Riordan-McKenna Institute following the schism, using the same initials as the original clinic.

Jurors in a Tarrant County District Court found that McKenna wasnt fairly compensated for the assets transferred to the Riordan Medical Institute or for the revenue generated at the competing business.

You see business splits quite a bit, but usually not something this egregious, said Derrick Boyd, McKennas lead trial lawyer from Boyd Powers & Williamson.

Riordan said he was disappointed in the decision and would be pursuing post-trial options.

We disagree mightily with the result in the trial and plan to present appropriate post-trial motions to the court and, if necessary, to appeal this unjust ruling result to the court of appeals, Riordan said.

McKennas dismissal from the Riordan-McKenna Institute caught the doctor off guard, Boyd said. On May 16, 2018, Riordans lawyer delivered McKenna a letter stating that Riordan wished to sever their business partnership.

The current board, which consists of Dr. Riordan and David Murfin, has determined that it is in the best interest of RMI to terminate your affiliation with RMI in all regards including, but not limited to, your role as medical director, the letter said. As such, Dr. Riordan requests that you turn in your keys to the RMI office.

The letter gave two options for the future of the company: a dissolution or a buyout. Under the buyout, Riordan offered to buy McKennas 45% stake in the company for $500,000.

Boyd said McKenna was denied access to company financial records when he questioned the suggested buyout compensation, inspiring McKenna to sue his former partner.

In the lawsuit that was decided Aug. 31, jurors said Riordan failed to comply with his fiduciary duty to the company and that McKenna, as a member of the institute, had a right to assert such a claim.

Under the decision, McKenna was awarded damages for his stake in the company, improper financial distributions to Riordan-owned entities and a 45% share of amounts improperly received by Riordan or Riordan-owned entities from operations at RMI after May 16, 2018.

The verdict also included $5 million in punitive damages, Boyd said.

Go here to read the rest:

Jury awards North Texas doctor $7.8 million in lawsuit over his partner locking him out - The Dallas Morning News

The theory is currently being investigated in the phase 3 SIERRA trial (NCT02665065) of the radio immunotherapy Iomab-B versus the standard of care (SOC). Preliminary safety data from the study showed that myeloablative conditioning with Iomab-Bled to lower rates of severe mucositis, febrile neutropenia, and sepsis compared with SOC, even though radiation was administered at a high dose. The early findings suggest that use of myeloablative conditioning with Iomab-Bmay be beneficial to elderly patients with relapsed/refractory AML prior to hematopoietic stem cell transplantation.

One-hundred fifty patients will be enrolled in the study, and preliminary safety results were available for 54. The cohort received a median dose of 636 mCi (range, 354-1027 mCi)of Iomab-B. The median dose of radiation to the marrow in the Iomab-B group was 4.9 Gy (range, 4.6-32 Gy)and to the GI tract was 2.8 Gy to GI tract.

In an interview with Targeted Oncology, Rajneesh Nath, MD, director of Stem Cell Transplant at Banner MD Anderson, discussed the need for novel treatment for elderly patients with relapsed/refractory AML and how the SIERRA trial is designed to help.

TARGETED ONCOLOGY: What are outcomes like for patients who cannot tolerate transplant. What was additionally done to help these patients in your study?

Nath: Acute myeloid leukemia is the disease of the elderly. The median age at diagnosis is about 68 years and it's continuing to increase 1 to 2 years. Traditionally, and in different database, we saw that as the patients get older with the diagnosis of AML, they don't tend to do well with whatever treatment we throw at them. And 1 to 2 years survival is of the order of 10% or less. Traditionally, these patients will get an induction chemotherapy, if they can tolerate it. If they go into complete remission, patients who would be eligible for as allogeneic stem cell transplant. There are a lot of beliefs about the elderly patients, most hematologists in have a set cutoff age for after which they will not refer patients to a transplant, but this is not the case anymore. There's several studies that have shown that older patients who undergo allergenic stem cell transplant are able to do equally as well as some of the younger patients.

What was the hypothesis targeted delivery of Iomab-B to the marrow in patients with relapsed/refractory AML?

Generally speaking, there are 2 kinds of transplant myeloablative and reduced intensity. Myeloablation goes with increased intensity of chemotherapy and higher doses of radiation. What happens is this increase intensity increases toxicity. With targeted Myeloablation, what we are doing is delivering radiation where it is needed, and that is to the bone marrow. So, what we are able to do is target radiation to the sites where there is leukemia, and at the same time, save the critical orders that include heart, lungs, kidneys.

In the particular study, what we show is that while we are able to deliver myeloablative doses of chemotherapy to the bone marrow, we can spare the GI tract, which means that there will be less mucositis and GI toxicity which will translate to a decrease in neutropenic fever and sepsis.

Can you provide an overview of the study?

This was an interim analysis of the SIERRA trial of Iomab-B in elderly relapsed/refractory patients with AML. The way that trial worked was if you are over the age of 55, and have a relapsed or refractory acute myelogenous leukemia, and you have a fully matched donor. These patients are randomized one to one either to the Iomab-B, which is the experimental arm or the standard of care arm. If they go to the Iomab-B, they get a transplant, even though they have an active disease at the time. If they go into remission, we look at what is the duration of remission, and the primary end point of the trial is 6-month duration of remission.

In that case that they are randomized to the standard of care, they can get whatever chemotherapy of the choosing of the treating oncologist, if they go into remission after receiving that chemotherapy, they can get a standard stem cell transplant or the treating physicians oncologist team, or if they do not go into remission, they can be crossed over to the Iomab-B arm. What we looked at was the toxicity in these 2 groups of patients.

What were the result of this study?

Only about 4% of the patients in Iomab-B arm had sepsis. This was in contrast to 13% of the patients who receive standard of care treatment. Also, with Iomab-B, we saw 40% neutropenic fever, which would be expected, and less than 10% of the patients had grade 3 or 4 mucositis.

What is next for this study?

Only 75% of the land enrollment is a complete. We expect to complete the study this year when total of 150 patients will be randomized. And the next million-dollar question is we have shown in several of the interim analyses that the procedure is safer and is not toxic. The next real question is, is this effective as compared to the standard of care treatment? Once the analysis is complete, we'll know the answer to that.

As this treatment strategy moves forward in clinical trial development, what is your vision for its future use in this patient population? Are there any other exciting strategies emerging for the older subgroup?

It's an exciting time to be treating elderly patients with acute myeloid leukemia. Until a couple of years ago, we didn't have anything for them, we would just see which patients would be eligible for induction which many of these patients were not. We recently had several new approvals for this disease.

One of the particular areas that I'm excited about is the use of combination of hypomethylating agents with venetoclax [Venclexta]. This combination is able to free a lot of elderly patients and put them into remission. It serves as a pathway to take them to stem cell transplant because the outcomes of stem cell transplant are better if they are done in remission. So, on one hand, we are able to put an increasing number of patients into remission and provide them a pathway for stem cell transplant. On the other hand, if this study works out, we will be having a pathway for patients who do not go into remission, also to proceed with an allergenic stem cell transplant.

In your opinion, what promise does myeloablative targeted conditioninghave for the future?

This technology, while initially may be approved for acute myeloid leukemia in the elderly, may have role in several other clinical situations, like patients who have comorbidities and are not able to get full intensity chemotherapy. We can also use this technology in patients who go into transplant with minimal residual disease, though these patients may be technically considered in remission. Because they have small amount of disease, they do not do as well as those patients who are transplanted who are in an MRD-negative state. So, it will open up a lot more areas where we can consider using this technology.

Reference:

Nath R, Choe H, Stiff P, et al.Myeloablative Targeted conditioning with anti-cd45 iodine (131I) apamistamab [Iomab-b] spares the GI tract and has low incidence of severe mucositis, febrile neutropenia and sepsis in the prospective, randomized phase 3 SIERRA trial for patients with relapsed or refractory acute myeloid leukemia (AML). Presented at: 2021 Transplantation & Cellular Therapy Meetings; February 8-12, 2021; Virtual. Abstract 59.

The rest is here:

Iomab-B Shows Early Promise Versus Standard Therapy in Elderly R/R AML - Targeted Oncology

The highly potent and selective non-covalent BTK inhibitor resulted in an overall response rate (ORR) of 52% (95% CI, 38%-65%) in patients with MCL (n = 56), with a 25% complete response (CR) rate, a 27% partial response (PR) rate, and a stable disease rate of 18%.

Among patients who were pretreated with BTK inhibitors (n = 52), the ORR achieved with pirtobrutinib was the same, at 52% (95% CI, 38%-66%); the CR, PR, and stable disease rates were 25%, 27%, and 17%, respectively. Notably, efficacy with the agent was also observed in those who previously underwent stem cell transplant (n = 9/14) or CAR T-cell therapy (n = 2/2), with rates of 64% and 100%, respectively.

The ORR with pirtobrutinib was higher in those with Waldenstrm macroglobulinemia (n = 19), at 68% (95% CI, 44%-87%), which included a PR rate of 47%, a molecular response (MR) rate of 21%, and a stable disease rate of 16%. BTK pretreated patients with Waldenstrm macroglobulinemia (n = 13) experienced an ORR of 69% (95% CI, 39%-91%), with a PR rate of 39%, a MR rate of 31%, and a stable disease rate of 8%.

The ORRs experienced in patients with Richters transformation (n = 8), follicular lymphoma (n = 8), marginal zone lymphoma (n = 9), and diffuse large B-cell lymphoma (n = 25) were 75% (95% CI, 35%-97%), 50% (95% CI, 16%-84%), 22% (95% CI, 3%-60%), and 24% (95% CI, 9%-45%), respectively.

Pirtobrutinib is well tolerated and exhibits promising efficacy in heavily pretreated patients with MCL and other non-Hodgkin lymphomas, lead study author Alvaro J. Alencar, MD, of Sylvester Comprehensive Cancer Center, and colleagues, wrote. Durable responses in BTK pretreated MCL are particularly notable, given poor outcomes with existing therapeutic options.

In the phase 1/2 BRUIN trial, investigators set out to evaluate the safety and efficacy of pirtobrutinib in previously treated patients with advanced B-cell malignancies. To be eligible for participation, patients needed to be 18 years of age or older, an ECOG performance status of 0 to 2, and active disease in need of treatment.

A total of 323 patients were enrolled to the trial; 203 of these patients were enrolled to the phase 1 escalation and expansion portion of the trial, where they received the agent at a once-daily dose ranging from 25 mg to 300 mg, and 120 patients to the phase 3 portion, where they received a once-daily dose of 200 mg.

Key end points of the trial include safety and tolerability, determining the maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D), pharmacokinetics, and efficacy with respect to ORR and duration of response based on disease criteria.

The median age of participants was 68.3 years, 69% were male, 50% had an ECOG performance status of 0, and the median number of prior lines of systemic therapy was 3. Previous treatments included BTK inhibitors, chemotherapy, anti-CD20 antibody, BCL-2 inhibitors, PI3K inhibitors, lenalidomide (Revlimid), CAR T-cell therapy, autologous stem cell transplant, and allogeneic stem cell transplant. The majority of patients who discontinued prior BTK inhibitors did so because of disease progression.

Among 323 patients included in the safety population, no dose-limiting toxicities were reported and the MTD had not been reached. The most frequent treatment-emergent adverse effects (TEAEs) experienced by 10% or more of patients included fatigue, diarrhea, and contusion. AEs of special interest included bruising, rash, arthralgia, hemorrhage, hypertension, atrial, and fibrillation/flutter.

Of these patients, 1.5% discontinued treatment because of treatment-related AEs. The RP2D for pirtobrutinib was established as once-daily 200 mg. No notable covalent BTK inhibitorassociated toxicities were rarely reported.

Longer follow-up is needed to better understand the pirtobrutinib safety profile associated with chronic administration, the study authors concluded.

See original here:

Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas - OncLive

Hematopoietic somatic cell Transplantation (HSCT) may be a specialized sort of blood somatic cell transplant therapy. The term hematopoietic refers to the function of the stem cells in citizenry . Stem cell refers to specialized somatic cell types which are capable of developing into specific cells like bone, muscle, blood, and nerve cells.

The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/1250

Hematopoietic somatic cell transplantation are often utilized in the treatment of certain cancers of the blood or bone marrow, like myeloma or leukemia. High prevalence of such diseases is predicted to assist in growth of the hematopoietic somatic cell transplantation (HSCT) market. consistent with Leukemia and Lymphoma Society, 176,200 people within the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2019.

The hematopoietic somatic cell transplantation (HSCT) market in North America is witnessing high growth, due to high adoption of allogeneic hematopoietic somatic cell transplant. Around 30,000 patients undergo allogeneic hematopoietic somatic cell transplant annually within the us .

Hematopoietic cell transplantation is that the transplantation of stem cells, generally derived from bone marrow, duct , or peripheral blood. It also can be allogenic, autologous or syngeneic. the foremost common sort of somatic cell transplant is that the allogenic transplant, which is actually the method of harvesting such stem cells that have the power to become many various specialized cell types, like bone, kidney, heart, liver, lungs, pancreas, nervous, and immune cells. However, approximately 20% to 85% of the patients develop acute Graft Versus Host Disease that affects the skin, gut, or liver. Such scenario hinders the expansion of hematopoietic somatic cell transplantation (HSCT) market.

There are different methods of transplant. just in case of a basic transplant, the stem cells are directly transplanted into an individuals veins, while a minimal invasive procedure also referred to as a micro-implantation requires the injection of the cells into the patients veins. supported the precise needs of the patient, the precise sort of transplant is completed . for instance , a toddler who has undergone bone marrow transplantation can continue to possess other somatic cell types utilized for an equivalent purpose. this is often one among the foremost commonly performed sorts of transplants.

High prevalence of red blood cell anemia is additionally expected to assist in growth of the hematopoietic somatic cell transplantation (HSCT) market. Specially created somatic cell therapies are often utilized in the treatment of red blood cell anemia. These cells are basically taken from the bone marrow of the person then induced to make a thick, jelly like substance. The patient will got to take medicine for a couple of days after the procedure to assist his bodily process the cells.

Hematopoietic cell transplantation has its own set of complications, which limit the expansion of the hematopoietic somatic cell transplantation (HSCT) market. a number of these include infection, allergies , bleeding, and scarring. Infection can occur if theres a severe immune deficiency. The patient also will need to take antibiotics to clear up the infections. If the stem cells are used, they need to be grown under very strict conditions to avoid rejection. Most surgeons attempt to perform this transplant first on those people that suffer from serious diseases like leukemia or cancer as these are the people that stand the simplest chance to achieve success .

Competitive Landscape

Key players operating in the Hematopoietic Stem Cell Transplantation (HSCT) Market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd.

We also offer 15% FREE Report customization.Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/1250

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

See the article here:

Hematopoietic Stem Cell Transplantation (HSCT) Market by Sales, Revenue, Price and Gross Margin (2021-2027) UNLV The Rebel Yell - UNLV The Rebel Yell